1 Comment


23andMe, the personal genetics company, has raised a $50 million Series D funding round to expand its users to one million individuals, drop the price of its Personal Genome Service to $99, and expand its infrastructure involved in its research capabilities.

Double Helix
photo: The Cancer Genome Atlas

23andMe, the genetics startup founded in 2006 to help consumers understand their genetic information, announced Tuesday that it’s raised a $50 million Series D funding round from new investor Yuri Milner as well as existing investors to in hopes of reaching one million customers. Currently, the service has 180,000 customers, and it is immediately lowering the price of its Personal Genome Service to $99.

Existing investors include the company’s CEO Anne Wojcicki, Google co-founder (and Wojcicki’s husband) Sergey Brin, New Enterprise Associates, Google Ventures and MPM Capital.

23andMe’s Personal Genome Service gives consumers the opportunity to understand their ancestry and genetic makeup, and it gives the company the chance to create a database of genetic information. By increasing the number of customers to one million, the company would have a larger database that would “enable groundbreaking research by creating an exponentially larger collective of actively engaged, genotyped individuals,” the company wrote in a press release.

The company also noted that the funding will allow it to “expand the necessary infrastructure to support growth in its research and operational capabilities, including product development, genetic research, software development, recruitment and marketing.”

You’re subscribed! If you like, you can update your settings

Related research

Subscriber Content

Subscriber content comes from Gigaom Research, bridging the gap between breaking news and long-tail research. Visit any of our reports to learn more and subscribe.

You're subscribed! If you like, you can update your settings

  1. Robert L. Greenberg Wednesday, December 12, 2012

    Putting this technology into the hands of individuals is potentially very disruptive to medicine and empowering to individuals–allowing people to take control their medical care. I’m looking forward to the future of decentralized genetics.

Comments have been disabled for this post